● Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

Condition: Advanced Cancer · Advanced Solid Tumors · Sponsor: Shanghai Allink Biotherapeutics Co., Ltd.

PhasePhase 1/Phase 2

Planned participants202

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK201. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK201 as a monotherapy in adult participants with Advanced Solid Tumors. The study will also identify recommended dose(s) for subsequent clinical studies of ALK201.

This description comes directly from the study's public registry record.

Talk to the study team

ALK Tang · +8618502921630 · xftang@allinkbio.com

Always discuss trial participation with your own doctor first.

Locations (38)

Denver Drug Development Unit	Denver, Colorado, United States	Recruiting
UCF Lake Nona Cancer Center	Orlando, Florida, United States	Recruiting
University Medical Center New Orleans	New Orleans, Louisiana, United States	Recruiting
Sarah Cannon Research Institute Oncology Partners	Nashville, Tennessee, United States	Recruiting
Cancer Care Wollongong	Wollongong, New South Wales, Australia	Recruiting
Sunshine Coast University Private Hospital	Birtinya, Queensland, Australia	Recruiting
Mater Cancer Care Center	South Brisbane, Queensland, Australia	Recruiting
Macquarie University Hospital	Macquarie, Australia	Recruiting
Anhui Provincial Cancer Hospital	Hefei, Anhui, China	Recruiting
Fujian Cancer Hospital	Fuzhou, Fujian, China	Recruiting
Fujian Medical University Union Hospital	Fuzhou, Fujian, China	Recruiting
The First Affiliated Hospital Of Xiamen University	Xiamen, Fujian, China	Recruiting

+ 26 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06656390